Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

Working Life Interview: Alison Muir, Oncology Product Strategy Director at Roche

November 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Working Life, feature, pharma

You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was …
Feature
roche

Roche’s risdiplam hits main goal in spinal muscular atrophy type 2 or 3

November 11, 2019 Research and Development, Sales and Marketing Roche, pharma, risdiplam, spinal muscular atrophy

Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam …
News
novartis_window

Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis

November 11, 2019 Research and Development, Sales and Marketing Novartis, nash, non-alcoholic steatohepatitis, pharma

The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR …
News
bavencio

Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

November 8, 2019 Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

In our rundown of the week’s most popular stories, President Donald Trump has named his first choice for the top …
News

Roche terminates Duchenne muscular dystrophy candidate due to poor clinical outlook

November 8, 2019 Medical Communications, Research and Development Duchenne Muscular Dystrophy, Roche, pharma

Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent …
News
astrazeneca_sign_sky

AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials

November 8, 2019 Medical Communications, Research and Development AstraZeneca, pharma, roxadustat

AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …
News

Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

November 8, 2019 Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …
News
johnson_and_johnson_jj_4

J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak

November 7, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Ebola, Janssen, Johnson & Johnson, pharma

Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply …
News
astrazeneca_plaque_42

AstraZeneca reveals three-pronged “large-scale” R&D initiatives in China

November 7, 2019 Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China

AstraZeneca has doubled down on its commitment to the Chinese region with the announcement of three “large-scale initiatives” in the …
News
paul-campanelli

Endo President and CEO to retire, search for a successor begins

November 7, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Endo pharma, appointment

Endo International has announced its “CEO succession plan”, revealing that the company’s Chief Executive and President Paul V Campanelli has …
News
takeda_usa_pharmaceuticals_u

Strong Phase 3 showing for Takeda’s dengue vaccine, but concerns remain over consistent coverage

November 7, 2019 Research and Development Takeda, dengue, pharma

Takeda has unveiled new data from its ongoing Phase 3 trial investigating the efficacy of its vaccine candidate TAK-003 in …
News
fdaoutsideweb

Aveo backs off on tivozanib approval after FDA calls for more conclusive data

November 6, 2019 Research and Development, Sales and Marketing Aveo Oncology, FDA, pharma

Aveo Oncology has hit another hurdle in its quest for approval of its vascular endothelial growth factor receptor tyrosine kinase …
News
shutterstock_243110086

Halozyme culls staff by 55% following Phase 3 metastatic pancreas cancer failure

November 6, 2019 Manufacturing and Production, Research and Development Halozyme, pharma, trial failure

Halozyme Therapeutics has announced it is to cull its workforce by more than half in the wake of the news …
News
takeda_usa_pharmaceuticals_u

Takeda to jettison non-core asset portfolio to Stada for $660 million

November 6, 2019 Research and Development, Sales and Marketing Stada, Takeda, pharma

Takeda has announced it is divesting a portfolio of its over-the-counter (OTC) and prescription drug products to Stada for a …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026